A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Inclusion Criteria: Retrospective cohort Adult/Adolescent Participant: * Adult/Adolescent study participant from any of the prior RSV MAT studies who have either received RSV MAT vaccine or control (placebo, Tdap or influenza vaccine). * Study participant: * who has reached 2 years+2 months post vaccine/control prior to/at enrolment or * who has not reached 2 years+2 months post vaccine/control prior to/at enrolment but is a Woman of Nonchildbearing Potential (WONCBP) at study enrolment, or recipient of bilateral tubal ligation prior to study enrolment. * Study participant with any pregnancy conceived post vaccination/control, that has reached Day 42 post-delivery prior to/at enrollment. * Provide signed and dated informed consent form. * Be willing to comply with all study requirements and be available for the duration of the study. Infant Participant: * Participant live born as the result of a pregnancy followed in an adult/adolescent participant in this study. * Signed and dated informed consent form obtained from the participant's parent(s)/LAR(s) prior to performance of any study-specific procedure. Prospective cohort Adult/Adolescent Participant: * Adult/adolescent study participant from any of the prior RSV MAT studies who have either received RSV MAT vaccine or control (placebo, Tdap or influenza vaccine). * Study participant: * who has not reached 2 years+2 months post vaccine/control prior to/at enrollment or * who has reached at least 2 years+2 months post vaccine/control but has an ongoing pregnancy (prior to Day 42 post-delivery) at enrollment. Participants who have reached 2 years post-vaccine/control before enrollment but are pregnant at enrollment will be enrolled and followed until Day 42 post-delivery for the pregnancy ongoing at enrollment. * Female participants of childbearing potential. * Provide signed and dated informed consent form. * Be willing to comply with all study procedures and be available for the duration of the study. Infant Participant: * Participant live born as the result of a pregnancy followed in an adolescent/adult participant in this study. * Participant's parent(s)/LAR(s), in the opinion of the investigator, can and will comply with the requirements of the protocol. * Signed and dated informed consent form obtained from the participant's parent(s)/LAR(s) prior to performance of any study-specific procedure. Exclusion Criteria: Adult/adolescent participant otherwise eligible for the prospective cohort: • Woman of Nonchildbearing Potential (WONCBP) at study enrollment, or recipient of bilateral tubal ligation prior to study enrollment, if she has not conceived a pregnancy post-vaccine/control and does not plan to use any additional measures to attempt to conceive a pregnancy (e.g., sterilization reversal or IVF). Infant participant: • Child in care.